Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Accounts Payables: 2023-2025

Historic Accounts Payables for CG Oncology (CGON) over the last 2 years, with Sep 2025 value amounting to $9.2 million.

  • CG Oncology's Accounts Payables fell 18.85% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year decrease of 18.85%. This contributed to the annual value of $6.5 million for FY2024, which is 101.02% up from last year.
  • As of Q3 2025, CG Oncology's Accounts Payables stood at $9.2 million, which was up 29.02% from $7.1 million recorded in Q2 2025.
  • Over the past 5 years, CG Oncology's Accounts Payables peaked at $11.3 million during Q3 2024, and registered a low of $3.2 million during Q4 2023.
  • Its 3-year average for Accounts Payables is $7.0 million, with a median of $6.9 million in 2024.
  • In the last 5 years, CG Oncology's Accounts Payables skyrocketed by 101.02% in 2024 and then declined by 18.85% in 2025.
  • Over the past 3 years, CG Oncology's Accounts Payables (Quarterly) stood at $3.2 million in 2023, then soared by 101.02% to $6.5 million in 2024, then fell by 18.85% to $9.2 million in 2025.
  • Its Accounts Payables stands at $9.2 million for Q3 2025, versus $7.1 million for Q2 2025 and $6.7 million for Q1 2025.